Welcome to Sopharma AD A Prominent Name in Public Healthcare!
Back to Sopharma Home page Contact us  
Welcome to www.sopharma.com
16 Iliensko Chausee St.
Sofia, Bulgaria 1220
 


Cardiovascular drugs

Antistenocardin
Atenolol
Captopril
Chlophadon
Chlophasolin
Corazol
Furanthril
Isodinit
Monisid
Naniprus
Pharmacynon
Prenylamin
Sydnopharm
Verapamil


Phytochemical Products from Plant origin

. Tribestan
Phytin
Carsil
Nivalin
Tabex
Palmcarotenol
Clinogel


Pharmaceutical substances

. Silymarin
. Cytisine
. Esculin
. Galantamine bromide
. Glaucin hydrobromide
. Phytin
. Peflavit
. Tribulus terrestris
. Valerian dry extract


Pharmaceutical products

Fifteen categories
 

 

 

 

FURANTHRIL

 
 
StockNo Product description
EB0280-424-10 FURANTHRIL AMPOULE 20 MG/2 ML
EB0280-424-32 FURANTHRIL TABL 40 MG X 50
 
COMPOSITION:
Furosemide 20 mg in one ampoule and 40 mg in one tablet.

ACTION:
Furanthril is a potent diuretic with a fast and short action, realized by the lumen side of the epithelium of the renal tubules in the ascending limb of Henle's loop. It increases the selective excretion of sodium ions to a maximum of 35 %, and stimulates the renin-angiotensin-aldosterone system, depending on the dose. Prior to the renal diuretic effect, furanthril reduces the overload of the heart by dilating the capacitive vessels, in preserved renal function and absence of marked edemas.

PHARMACOKINETICS:
The diuretic effect of the drug is about 6 h after oral administration, intravenously - from 2 to 3 h. Half-elimination time in serum after oral administration of 40 mg furanthril is about 3.5 h in healthy subjects and in patients with impaired renal function it is 13.5 h on the average.
More than 90 % of furanthril were found to be excreted through the kidneys.

INDICATIONS:
Edemas resulting from cardiac, hepatic and renal diseases, and as a result of burns. Acute and chronic cardiovascular insufficiency, in combination with other drugs. Hypertension (particularly in affected renal function and hypertonic crises).
In the complex therapy of pulmonary and cerebral edema.
In toxicoses of pregnancy progressing with oliguria.
For maintaining forced diuresis in intoxications.
For prophylaxis of acute renal insufficiency (threatening or advanced shock). For treatment of hypercalcemic crises.

CONTRAINDICATIONS:
Grave hepatic insufficiency (hepatic coma), renal insufficiency accompanied by anuria or oliguria; hypokalemia; hypersensitivity to furanthril and sulfonamides; reduced blood volume (hypovolemia), with or without concomitant reduction of blood pressure (hypotension).

SIDE EFFECTS:
Hypokalemia, hyponatremia, hypocalcemia, hypovolemia are likely to occur after long-term administration of high doses of furanthril, as well as dehydration and a tendency to thrombosis and other disorders of the water-electrolyte balance of the organism.
Sometimes allergic reactions can be observed in predisposed patients: skin rashes and changes in the blood count (leukopenia, agranulocytosis, thrombocytopenia). Anaphylactic shock is a rare phenomenon.
A transitory elevation of creatinine, urea, chelesterol and triglycerides in blood may result from furanthril treatment.
An existing diabetes can be deteriorated in rare cases or a latent diabetss can be manifested.
Transotory disorder in hearing and orthostatic collapse are possible after last intravenous administration of furanthril.

PRECAUTIONS:
Furanthril should be administered to pregnant women only after accurate evaluation of the indications. To breast-feeding mothers the fact that the drug passes into the milk and that it suppresses lactation should be borne in mind. It is recommended to stop breats-feeding in such cases.
Furanthril administration to drivers and to subjects operating machines can disturb their fitness for active performance.

DRUG INTERACTIONS:
The diuretic activity of furanthril decreases after combined therapy with enzyme inductors as phenobarbital, phenytoin, etc. The simultaneous administration of furanthril and some antibiotics (aminoglucosides, cefalosporins and polymyxins) and cysplatinum enhance the ototoxic risk.
Combined administration with cardiac glycosides and laxatives involves a higher risk of hypokalemia.
Sometimes furanthril can weaken the effects of salicylates, theophyllin, lithium and curare-like muscular relaxants. It potentiates the action of the hypotensive drugs. The nonsteroid antiphlogistic agents (indomethqacin) weaken furanthril action, even acute renal insufficiency is likely to occur in hypovolemic states.

DOSAGE AND ADMINISTRATION:
It orally or parenterally administered in edemas of renal, hepatic and cardiac origin.
Oral administration: initial dose 40 mg, in the absence of diuretic effect the dose is repeated after 6 h up to a maximum of 160 mg. The daily maintenance dose ranges between 40 to 80 mg.
For children - orally: 1-2 mg/kg body weight.
Parenteral administration: initial dose 20 mg. Whenever necessary, the dose is increased from 40 to 200 mg. The injection rate should not exceed 4 mg/min.
Acute cardiac insufficiency and pulmonary edema: initial dose 20-40 mg intravenously, in the absence of effect - the same dose is repeated 30 min to 1 h later.
Chronic cardiac insufficiency: usually 20 to 40 mg daily orally or intravenously are prescribed.
Cerebral edema and edemas after burn: the dosage is individual. The daily dose or single dose ranges between 40 and 100 mg, in cases of impaired renal function - up to 250 mg orally or intravenously.
Hypotension and hypertonic crises: 40 mg daily, orally, prescribed together with other pharmaceuticals. In severe states - 20-40 mg furosemide intravenously.
Forced diuretics in endogenous and exogenous intoxications and prophylaxis of acute renal insufficiency: the dosage depends on the necessary volume of diuresis - 20 to 100 mg intravenously every hour, with control of the water-electolyte balance in organism.
Hypercalcemic crisis: individual dosage - most often: 40 to 250 mg/hour.
Parenteral administration to breast-fed infants and children below the age of 15: furanthril is parenterally administered only in life-threatening conditions, the mean daily dose being 0.5 mg/kg body weight, in exceptional cases it can be administered intravenously in a dose not exceeding 2 mg/kg body weight.

MEDICINAL FORM AND PACKAGE:
Packages with 10 and 50 ampoules of 20 mg/2 ml.
Packages with 50 tablets of 40 mg.

STORAGE:
At moderate temperature (15-30 C), protected from light.

EXPIRY:
Ampoules - 3 (three) years.
Tablets - 2 (two) years.

 

 

Central nervous system Bellergamin Centrophenoxine Chlorazin Cinnarizine Diazepam Haloperidol Lydol Morphine Natrium bromatum Phenobarbital Piracetam Tempalgin Tilidine adrenaline Atropine Lidocaine Nivabex Nivalin Pymadin Tabex Cardiovascular Antistenocardin Atenolol Captopril Chlophadon Chlophazolin Diltiazem Furosemide Isocor Naniprus Pentofyllin Pharmacynon Vasopren Digestive system Ranitidine Sopral Pulmonary system Bromhexin Broncholytin Codterpin Dimex Glauvent Salbutamol Sophafyllin Amidophen Analgin Feloran Indomethacin Paracetamol Piroxicam Buscolysin Papaverine Antibiotic Amikacin Chlorquinaldol Ethambutol Gentamicin Rimicid Progesterone Testosterone Allergosan Ketotifen Vitamins, Minerals & Enzymes Calcium Phospho C Deavit Deflamol Peflavit C Vitamins Furotalgin Pilocarpine Rhinolex Sulfacetamide Mycodermin Revulsan Univertan Zinc ointment Phytin Tribestan Antistrumin Bisacodyl Calcium gluconicum Glibenclamide Methilprednisolone Natrium citricum Natrim chloratum Phlebescin

1999-2001 Sopharma USA Corporation. All rights reserved.
Copyright, Trademark, Disclaimer and Privacy statement.

A service of Bulgarian Pharmaceutical Group Ltd.

EB0280 01/28/2001